Five Oceans Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$760K Buy
4,009
+6
+0.1% +$1.13K 0.24% 54
2026
Q1
$789K Buy
4,003
+6
+0.2% +$1.16K 0.29% 43
2025
Q4
$735K Hold
3,997
0.26% 48
2025
Q3
$613K Buy
3,997
+201
+5% +$30.4K 0.23% 56
2025
Q2
$531K Hold
3,796
0.23% 57
2025
Q1
$558K Sell
3,796
-1,172
-24% -$170K 0.27% 56
2024
Q4
$651K Buy
4,968
+530
+12% +$74.2K 0.3% 53
2024
Q3
$692K Buy
4,438
+359
+9% +$58K 0.33% 53
2024
Q2
$636K Buy
4,079
+596
+17% +$89.7K 0.33% 52
2024
Q1
$472K Hold
3,483
0.24% 68
2023
Q4
$469K Buy
3,483
+41
+1% +$5.33K 0.26% 71
2023
Q3
$466K Hold
3,442
0.3% 67
2023
Q2
$493K Hold
3,442
0.32% 69
2023
Q1
$478K Hold
3,442
0.31% 74
2022
Q4
$467K Sell
3,442
-1
-0% -$125 0.32% 70
2022
Q3
$378K Buy
3,443
+1,230
+56% +$156K 0.3% 73
2022
Q2
$292K Buy
2,213
+199
+10% +$26.1K 0.22% 91
2022
Q1
$267K Hold
2,014
0.24% 85
2021
Q4
$235K Sell
2,014
-20
-1% -$2.35K 0.21% 92
2021
Q3
$244K Buy
+2,034
New +$237K 0.28% 79

Other funds holding AZN

Five Oceans Advisors's AZN Position: Q2 2026 in Review

Five Oceans Advisors increased its AstraZeneca (AZN) stake by 0.15% in Q2 2026, buying an estimated $1.13K and bringing the position to 4,009 shares worth $760K. The position accounts for 0.24% of the portfolio, ranked #54.

Five Oceans Advisors first reported a position in AZN in Q3 2021 and has held it in 20 quarters since. The position peaked at $789K in Q1 2026. 233 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Five Oceans Advisors held 4,009 shares of AstraZeneca worth $760K as of Q2 2026.
  • Five Oceans Advisors bought 6 AstraZeneca shares in Q2 2026, an estimated $1.13K.
  • AstraZeneca made up 0.24% of Five Oceans Advisors's portfolio in Q2 2026, its #54 holding.
  • Five Oceans Advisors first reported a position in AstraZeneca in Q3 2021 and has held it in 20 quarters since.
  • Five Oceans Advisors's AstraZeneca position peaked at $789K in Q1 2026.
  • 233 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Five Oceans Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.